100 results about "Coboglobin" patented technology

The invention provides a hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit comprises an upper shell, a lower shell, an immunostrip, test paper and the like; a gold-labeled composite containing a hemoglobin monoclonal antibody, a hemoglobin-haptoglobin composite monoclonal antibody and a transferrin monoclonal antibody is scribed on a nitrocellulose membrane; 3 test lines, a quality control line (15) and a gold-labeled composite membrane scribing line (8) are arranged on the nitrocellulose membrane in parallel. The invention further provides a preparation method and a detection method of the hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit is convenient and simple in operation, stable in performance and accurate in result, has a relatively good reference value for early diagnosis and identification of colorectal cancer or colon cancer tumor or other tumors with lower gastrointestinal bleeding symptoms in clinic, significantly improves the positive detection rate of digestive hemorrhagic diseases, is suitable for clinical hospital examination and household self-examination, and provides measures for large-scale general examination of such diseases.

The invention provides a method of diagnosing tuberculosis (TB) in a test subject, said method comprising: (i) providing expression data of two or more markers in a subject, wherein at least two of said markers are selected from transthyretin, neopterin, C-reactive protein (CRP), serum amyloid A (SAA), serum albumin, apoliopoprotein-A1 (Apo-A1), apolipoprotein-A2 (Apo-A2), hemoglobin beta, haptoglobin protein, DEP domain protein, leucine-rich alpha-2-glycoprotein (A2GL) and hypothetical protein DFKZp667I032; and (ii) comparing said expression data to expression data of said marker from a group of control subjects, wherein said control subjects comprise patients suffering from inflammatory conditions other than TB, thereby determining whether or not said test subject has TB.

Method and pharmaceutical composition for treating anemia related symptoms. The method and formulation involve the use of one or more cucurbitacin analogs as active ingredients, for example, cucurbitacin D, which are capable of increasing hemoglobin expression, reactivating fetal or adult hemoglobin and inducing γ-globin.

The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.

Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta / delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact / cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase / arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO / 2008 / 031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.

The invention belongs to the field of biological chemical detection and particularly relates to a method of determining the ratio of a globin chain alpha to a globin chain beta in hemoglobin and application of the method in detection of beta-mediterranean anemia. The method comprises the steps that hemoglobin samples are taken and split to obtain split fragments of the globin chain alpha and split fragments of the globin chain beta; one split fragment of the globin chain alpha and one split fragment of the globin chain beta are selected and used as sign peptide fragments; a mass spectrum is used for determining the concentration of the sign peptide fragment of the globin chain alpha and the concentration of the sign peptide fragment of the globin chain beta; the ratio of the globin chain alpha to the globin chain beta is expressed just by the ratio of the concentration of the sign peptide fragment of the globin chain alpha to the concentration of the sign peptide fragment of the globin chain beta. According to the method, by means of quantitative analysis of the ratio of the globin chain alpha to the globin chain beta, different types of beta-mediterranean anemia can be identified at an early stage, and severe, medium and mild beta-mediterranean anemia can be identified.

A method for purification of uncatalyzed natural fuels in liquid state from metal ions by removing at least one compound selected from the group consisting of natural occurring contaminating porphyrins, metalloporphyrins, chlorins and naturally occurring degradations products of these compounds, such as petroporphyrins, containing said metal ions from the fuels. At least one hemeprotein in apo-form selected from the group consisting of globins, peroxidases, pyrrolases and cytochromes having high affinity for porphyrins is added to the fuels. The hemeprotein is mixed with the fuels in such a way that the porphyrins is bounded to the hemeprotein. The hemeprotein with bound contaminating porphyrins is removed so as to obtain purified fuels. The invention relates also to the use of at least one hemeprotein selected from the group consisting of globins, peroxidases, pyrrolases and cytochromes having high affinity for porphyrins for the purification of uncatalyzed natural fuels in liquid state from metal ions.

A method is provided for diagnosing appendicitis in a patient that includes identifying at least one symptom of appendicitis in the patient and identifying the presence of at least one molecule differentially associated with appendicitis in a fluid or tissue sample of said patient. MRP-8 / 14 and haptoglobin are examples of molecules differentially associated with appendicitis. Devices and kits for performing the appendicitis assays of this invention are also provided. In one embodiment, the device is in a flow-through immunoassay format for testing blood samples. Further, methods for screening for molecules differentially associated with appendicitis are provided that include the use of samples from patients being operated on for suspected appendicitis.

The invention relates to prostatic cancer markers from a prostatic secretion, and discloses a group of new prostatic cancer markers comprising Haptoglobin alpha-chains, Fibronectin1, Albumin and / or SERPINB1. In the prostatic secretion, the expression of the above proteins in prostatic cancer patients is substantially higher than the expression in non-cancer patients, so reagents or kits for the diagnosis, the assessment and the prognosis of the prostatic cancer can be developed based on the proteins.

A method for detecting a haptoglobin-matrix metalloproteinase 9 (Hp-MMP9) complex in a biological sample. The sample includes incubating the biological sample with a capture reagent immobilized on a solid support to bind Hp-MMP9 to the capture reagent. The capture reagent includes a monoclonal antibody that binds MMP9. The method detects Hp-MMP9 bound to the immobilized capture reagent by contacting the bound Hp-MMP9 with a detectable antibody that binds to Hp.

The invention is directed to a more efficient lentiviral vector comprising a nucleic acid sequence encoding a human β-globin protein or a human γ-globin protein, which is oriented from 5′ to 3′ relative to the lentiviral genome. The invention also provides a composition and method utilizing the lentiviral vector.

Provided herein are methods for the diagnosis of obstructive airways diseases such as asthma and chronic obstructive pulmonary disease, and the discrimination between such diseases based on the expression profiles of biomarker proteins and combinations of biomarker proteins. In particular embodiments the biomarker proteins are selected from ceruloplasmin, haptoglobin, hemopexin, -2-macroglobulin, prothrombin, immunoglobulin A and complement factor H.

The invention discloses a method for separating copper proteome by using copper-chelated magnetic beads, and relates to the technical field of protein chemistry. The method comprises the following steps: taking a biological tissue or cell, after fully grinding with liquid nitrogen, adding protein extracting liquid, and after uniformly mixing, carrying out low-temperature centrifugation, so as to obtain a denatured protein solution; mixing the copper-chelated magnetic beads with the denatured protein solution, and incubating to obtain a magnetic bead protein mixed solution; adding a buffer solution 1 with the volume 1 time of that of the magnetic bead protein mixed solution into the magnetic bead protein mixed solution for suspension, pouring half of the supernate under the external magnetic field, and repeating for 4-5 times to obtain a mixed solution A; adding a buffer solution 2 with the volume 1 time of that of the mixed solution A into the mixed solution A, separating all the specific copper-binding proteins, namely, the copper proteome, and collecting the copper proteome under the external magnetic field. According to the method, the metalloproteome is separated under a denaturing condition by using magnetic bead-IDA, so that the procedures are greatly simplified, and the obtaining efficiency of metalloproteins is improved; a method suitable for separating the metalloproteome from the tissue or cell under the excess heavy metal treatment condition is established.

Disclosed is a test paper for detection of diabetic nephropathy, which includes a water-absorbing filter paper, a glass fiber membrane and a NC membrane, all of which are stacked successively from top to bottom. The test paper has a T1 testing region, a T2 testing region and a T3 reference region arranged along a transverse direction; the NC membrane is coated by urinary microalbumin antibodies in the T1 testing region, is coated by urinary haptoglobin antibodies in the T2 testing region and is coated by mouse anti-human IgG antibodies in the T3 reference region; and the glass fiber membrane is coated by urinary microalbumin labeled with colloidal gold in the T1 testing region, is coated by urinary haptoglobin labeled with colloidal gold in the T2 testing region and is coated by mouse anti-human IgG albumen labeled with colloidal gold in the T3 reference region.

The present invention relates to genetically edited swine which produce CD163 protein in which the scavenger receptor cysteine-rich 5 (SRCR5) domain (also known as CD163 domain 5) has been deleted. Such swine have been found to be healthy and do not exhibit negative properties, and are resistant to PRRSV infection. CD163 expressed in the edited swine also demonstrates retention of the ability to function as a haemoglobin-haptoglobin scavenger. Methods of producing such swine are also provided.

The invention relates to a detection method for methamphetamine (METH) addiction and application of a complement factor H (CFH) to genetic expression products of an METH addiction related group. On the basis of a great number of experiments, the stable expression of the CFH, alpha-1-acid glycoprotein 2, transthyretin, apolipoprotein L1 and haptoglobin in the blood serum of an METH addiction patient is up-regulated, and the CFH, the alpha-1-acid glycoprotein 2, the transthyretin, the apolipoprotein L1 and the haptoglobin can serve as the genetic expression products which are related to METH addiction. The content of CFH proteins in human serum is quantitatively detected by using an immunoblotting method or an enzyme linked immunosorbent assay kit, and expression up-regulation of the content of the CFH proteins is applicable to a method for identifying the METH addiction.

This invention provides novel assays for the detection of dysfunctional HDL. The assays are good diagnostics and / or prognostics for atherosclerosis or other pathologies characterized by an inflammatory response. In certain embodiments the methods involve measurements of heme-related HDL-associated proteins (e.g., haptoglobin, hemopexin, etc.), and / or measurements of the relative distribution of HDL-associated proteins between HDL and the non-lipoprotein fractions of plasma / serum, and / or measurements of the ability of pro-inflammatory HDL to consume nitric oxide, and / or measurement of the ability of HDL to inhibit LDL aggregation.

Compositions that include a globin, such as hemoglobin, in a relaxed state are described. Globin molecules in a relaxed state (R state) have a higher binding affinity for carbon monoxide and oxygen than globin molecules in a tense state (T state). Hemoglobin in a relaxed state can be, for example, hemoglobin that is substantially free of 2,3-diphosphoglycerate or hemoglobin that includes a beta-Cys93 that is covalently modified to inhibit one or both salt bridges between beta-Asp94, beta-His146 and alpha-Lys40. Methods for using these compositions, such as for treating carbon monoxide poisoning, and methods for producing these compositions, are also disclosed.

The invention provides a cytokine-induced killer cell activity-associated protein and an application thereof, relates to an immune cell activity-associated protein and especially relates to influences of haptoglobin on variation of cell activity of cytokine-induced killer (CIK) cells. The expression of the haptoglobin at a protein level and a nucleic acid level is significantly increased with enhancement of the activity of the CIK cells, which means that a positive correlativity exists between the haptoglobin and the activity of the cytokine-induced killer cells. The invention provides an index of detection of an activity intensity of the CIK cells, or provides basis for researching a recombinant protein and a relative medicine which are used for improving an immune system with the haptoglobin as an active component.

The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.

The present invention provides an anti-hypertensive agent. The anti-hypertensive agent of the present invention contains, as an active ingredient, at least one peptide selected from the group consisting of peptides originally derived from globin proteolysate, each of which consists of one of the following amino acid sequences (1) to (6), or a globin proteolysate containing at least one of the peptides: (1) Val-Val-Tyr-Pro (SEQ ID: NO. 1); (2) Trp-Gly-Lys-Val-Asn (SEQ ID: NO. 2); (3) Trp-Gly-Lys-Val (SEQ ID: NO. 3); (4) Trp-Gly-Lys (SEQ ID: NO. 4); (5) Ala-Ala-Trp-Gly-Lys (SEQ ID: NO. 5); and (6) Phe-Glu-Ser (SEQ ID: NO. 6).

The invention provides an assay method for determining a level of haptoglobin in a sample comprising the steps of: (i) mixing haemoglobin with the sample to be assayed so as to form a haptoglobin-haemoglobin complex with haptoglobin present in the sample; (ii) contacting the product of step (i) with reagents for generating hydrogen peroxide and one or more chromogens which undergo a spectroscopically detectable change when peroxidase activity is present, in the presence of a buffer, under conditions in which hydrogen peroxide is generated from said reagents and forms a substrate for the peroxidise activity of the haptoglobin-haemoglobin complex present, and wherein the pH of the buffer is within a range which is sufficiently low that the peroxidise activity of any uncomplexed haemoglobin is substantially suppressed but sufficiently high that hydrogen peroxide generation occurs; (iii) determining the peroxidase activity of the haptoglobin-haemoglobin complex by measuring the change in an optical property of the reaction mixture; and (iv) correlating the level of peroxidise activity of the haptoglobin-haemoglobin complex with the amount of haptoglobin in the sample. A kit for use in such a method is also provided.

The invention relates to the technical field of immunodiagnosis, and discloses colloidal gold immunochromatography test paper for rapidly diagnosing hemoglobin and haptoglobin hemoglobin complex and apreparation method thereof, aiming at the problem of inaccurate detection result caused by easy damage of pepsase to hemoglobin in digestive tracts in the prior art. The method specifically comprisesthe following steps: 1) preparing a first detection line T and a first quality control line C; 2) preparing a second detection line T and a second quality control line C; 3) preparing a gold-labeledpad; 4) preparing the test paper: sequentially connecting and assembling the water absorption pad, the sample pad, the microsphere probe treatment pad, the antibody-coated modified nitrocellulose membrane and the PVC bottom plate to obtain a finished product. The hemoglobin and hemoglobin combined globin compound is adopted for combined detection, the detection sensitivity of occult blood including upper gastrointestinal hemorrhage is improved, operation is easy, convenient and rapid, the result is visually and accurately displayed, sensitivity is high, specificity is good, and the preparationprocess is simple.

The present invention provides a method of stabilizing a protein. The method includes a step of causing a protein contained in a specimen derived from a living body to coexist with an arylboronic acid. The protein contained in the specimen derived from the living body is at least one type selected from the group consisting of hemoglobin, haptoglobin, and a hemoglobin-haptoglobin complex. According to the present invention, it is possible to stabilize a protein such as a blood protein contained in the specimen derived from a living body. The present invention further provides a stabilizing solution for stabilizing a protein contained in a specimen derived from a living body and a method and a kit for detecting a protein contained in a specimen derived from a living body.

The present disclosure provides expression vectors comprising at least two nucleic acid sequences, namely a nucleic acid sequence encoding an anti-HPRT RNAi, and a nucleic acid sequence encoding a gamma globin gene. In some embodiments, the viral vector is a self-inactivating lentiviral vector. In some embodiments, the gamma-globin gene is used to genetically correct sickle cell disease or β-thalassemia or to reduce symptoms thereof.